Skip to main content

Testosterone Therapy

  • Chapter
Andrology
  • 349 Accesses

Abstract

All forms of hypogonadism described in the previous chapters associated with Leydig cell insufficiency require testosterone therapy. In secondary hypogonadism long-term testosterone therapy is also indicated. This is only to be interrupted for GnRH or gonadotropin therapy when offspring are desired.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Atkinson L, Chang Y-L, Snyder PJ (1998) Long-term experience with testosterone replacement through scrotal skin. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 365–388

    Chapter  Google Scholar 

  • Bagatell CJ, Heimann JR, Rivier JE, Bremner WJ (1994) Effects of endogenous testosterone and estradiol on sexual behaviour in normal young men. J Clin Endocrinol Metab 78:711–716

    Article  PubMed  CAS  Google Scholar 

  • Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E (1986) Transdermal testosterone substitution therapy for male hypogonadism. Lancet 11:943–946

    Article  Google Scholar 

  • Barratt-Connor E, von Mühlen DG, Kritz-Silverstein D (1999) Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. J Clin Endocrinol Metab 84:573–577

    Google Scholar 

  • Behre HM, Nieschlag E (1992) Testosterone buciclate (20-Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting testosterone ester. J Clin Endocrinol Metab 75:1204–1210

    Article  PubMed  CAS  Google Scholar 

  • Behre HM, Nieschlag E (1998) Comparative pharmacokinetics of testosterone esters. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 329–348

    Chapter  Google Scholar 

  • Behre HM, Böckers A, Schlingheider A, Nieschlag E (1994a) Sustained suppression of serum LH, FSH testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin Endocrinol 40:241–248

    Article  CAS  Google Scholar 

  • Behre HM, Bohmeyer J, Nieschlag E (1994b) Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal contrais. Clin Endocrinol 40:341–349

    Article  CAS  Google Scholar 

  • Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82: 2386–2390

    Article  PubMed  CAS  Google Scholar 

  • Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E (1999a) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I-studies. Eur J Endocrinol 140:414–419

    Article  PubMed  CAS  Google Scholar 

  • Behre HM, von Eckardstein S, Kliesch S, Nieschlag E (1999b) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over seven to ten years. Clin Endocrinol 50:629–635

    Article  CAS  Google Scholar 

  • Bhasin S (ed) (1998) The therapeutic role of androgens. Baillières Clin Endocrinol Metab 12(3)

    Google Scholar 

  • Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirin M (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab 74:75–83

    Article  PubMed  CAS  Google Scholar 

  • Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1–7

    Article  PubMed  CAS  Google Scholar 

  • Bhasin S, Bross R, Storer TW, Casaburi R (1998) Androgens and muscles. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 209–227

    Chapter  Google Scholar 

  • Brämswig JH, Nieschlag E, Schellong G (1984) Pituitary-gonadal function in boys after high-dose testosterone treatment of excessively tall stature. Acta Endocrinol 107:97–103

    PubMed  Google Scholar 

  • Bundesgesundheitsamt (1990) Negativ-Monographien zu anabolen Steroiden: Stanozolol (Bundesanzeiger 1990, Nr. 18), Metenolon (Bundesanzeiger Nr. 48,1990), Oxabolon (Bundesanzeiger Nr. 111,1990), Androstanolon (Bundesanzeiger Nr. 240, 1990) Nandrolon (Bundesanzeiger Nr. 69, 1993), Clostebol (Bundesanzeiger Nr. 132,1993), Chlordehydromethyltestosteron (Bundesanzeiger Nr. 72,1994)

    Google Scholar 

  • Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ (1992) A long-term prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypogonadal men. J Androl 13:297–304

    PubMed  CAS  Google Scholar 

  • Carani C, Bancroft J, Granata A, Del Rio G, Marrama P (1992) Testosterone and erectile function: nocturnal penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 17:647–654

    Article  PubMed  CAS  Google Scholar 

  • Christiansen K (1998) Behavioural correlates of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 107–142

    Chapter  Google Scholar 

  • Clopper RR, Voorhess ML, MacGillivray MH, Lee PA, Mills B (1993) Psychosexual behaviour in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement. Psychoneuroendocrinology 18:149–161

    Article  PubMed  CAS  Google Scholar 

  • Cunningham GR, Hirshkowitz M, Kroenman SG, Karacan I (1990) Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab 70:792–797

    Article  PubMed  CAS  Google Scholar 

  • de Waal WJ, Vreeburg JTM, Bekkering F, de Jong FH, de Muinck Keizer-Schrama SMPF, Drop SLS, Weber RFA (1995) Highdose testosterone therapy for reduction of final height in constitutionally tall boys: does it influence testicular function in adulthood? Clin Endocrinol 43:87–95

    Article  Google Scholar 

  • Delanoe D, Fougevrollas B, Meyer L, Thonneau P (1984) Andro-genisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 1:276

    Article  PubMed  CAS  Google Scholar 

  • Dobs AS, Hoover DR, Chen MC, Allen R (1998) Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin Endocrinol Metab 83:33–39

    Article  PubMed  CAS  Google Scholar 

  • Drop SLS, de Waal J, de Muinck Keizer-Schrama SMPF (1988) Sex steroid treatment of constituionally tall stature. Endocr Rev 19:540–558

    Article  Google Scholar 

  • von Eckardstein A (1998) Androgens, cardiovascular risk factors and atherosclerosis. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New, pp 229–257

    Chapter  Google Scholar 

  • Finkelstein JS, Klibanski A (1990) Effects of androgens on bone metabolism. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution. Springer, Berlin Heidelberg New York, pp 204–215

    Chapter  Google Scholar 

  • Gooren LJG (1998) A ten year safety study on the oral androgen testosterone undecanoate. J Androl 15:212–215

    Google Scholar 

  • Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82:3793–3796

    Article  PubMed  CAS  Google Scholar 

  • Handelsman DJ (1998) Clinical pharmacology of testosterone pellet implants. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 348–364

    Google Scholar 

  • Horowitz M, Wishart JM, O’Loughlin PD, Morris HA, Need AG, Nordin BEC (1992) Osteoporosis and Klinefelter-syndrome. Clin Endocrinol 36:113–118

    Article  CAS  Google Scholar 

  • Jockenhövel F, Vogel E, Reinhardt W, Reinwein D (1997) Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 2:293–298

    PubMed  Google Scholar 

  • Jockenhövel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Müller-Wieland D, Krone W (1999) Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 48:590–596

    Article  PubMed  Google Scholar 

  • Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ (1999) Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol 51:469–471

    Article  CAS  Google Scholar 

  • King DS, Sharp RL, Vukovich MD, Brown GA, Reifenrath TA, Uhl NL, Parsons KA (1999) Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA 281:2020–2028

    Article  PubMed  CAS  Google Scholar 

  • Knussmann R, Christansen K, Kannmacher J (1992) Relations between sex hormone levels and character of hair and skin in healthy young men. Am J Phys Anthropol 88:59–67

    Article  PubMed  CAS  Google Scholar 

  • Knuth UA, Maniera H, Nieschlag E (1989) Anabolic steroids and semen parameters in body builders. Fertil Steril 52: 1041–1047

    PubMed  CAS  Google Scholar 

  • Kochakian CD (ed) (1976) Anabolic androgenic steroids. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 43)

    Google Scholar 

  • Kopera H (1985) The history of anabolic steroids and a review of clinical experiences with anabolic steroids. In: Eickelboom FS, van der Vies J (eds) Anabolics in the 80s. Acta Endocrinol [Suppl] 217:11–18

    Google Scholar 

  • Leifke E, Körner HC, Link TM, Behre HM, Peters PE, Nieschlag E (1998) Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 138:51–58

    Article  PubMed  CAS  Google Scholar 

  • Lemcke B, Zentgraf J, Behre HM, Kliesch S, Nieschlag E (1996) Long-term effects on testicular function of high-dose testosterone treatment for excessively tall stature. J Clin Endocrinol Metab 81:296–301

    Article  PubMed  CAS  Google Scholar 

  • Meikle AW (1998) A permeation-enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 389–422

    Chapter  Google Scholar 

  • Morales A, Johnston B, Heaton JP, Lundie M (1997) Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 157:849–854

    Article  PubMed  CAS  Google Scholar 

  • Nieschlag E (1981) Ist die Anwendung von Methyltestosteron obsolet? Dtsch Med Wochenschr 106:1123

    Article  PubMed  CAS  Google Scholar 

  • Nieschlag E (1992) Testosteron, Anabolika und aggressives Verhalten bei Männern. Dtsch Ärztebl 89:2967–2972

    Google Scholar 

  • Nieschlag E, Behre HM (eds) (1998a) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Nieschlag E, Behre HM (1998b) Pharmacology and clinical use of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 293–328

    Chapter  Google Scholar 

  • Nieschlag E, Nieschlag S, Behre HM (1993) Life expectancy and testosterone. Nature 366:215

    Article  PubMed  CAS  Google Scholar 

  • Nieschlag E, Büchter D, von Eckardstein S, Abshagen K, Behre HM (1999) Repeated intramuscular injections of testosterone undecanoate for substitution therapy of hypogonadal men. Clin Endocrinol 51:757–763

    Article  CAS  Google Scholar 

  • Randall VA (1998) Androgens and hair. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 169–186

    Chapter  Google Scholar 

  • Schaison G, Couzinet B (1998) Percutaneous dihydrotestosterone treatment. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 423–436

    Chapter  Google Scholar 

  • Schürmeyer T, Nieschlag E (1984) Comparative pharmacokinetics of testosterone enanthate cyclohexanecarboxylate as assessed by serum and saliva testosterone in normal men. Int J Androl 7:181–187

    Article  PubMed  Google Scholar 

  • Schürmeyer T, Wickings EJ, Freischem CW, Nieschlag E (1983) Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol 102:456–462

    PubMed  Google Scholar 

  • Schürmeyer T, Jung K, Nieschlag E (1984) The effect of a 1100 km run on testicular, adrenal and thyroid hormones. Int J Androl 7:276–282

    Article  PubMed  Google Scholar 

  • Salehian B, Wang CH, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS (1995) Pharmacokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparision to testosterone enanthate. J Clin Endocrinol Metab 80:3567–3575

    Article  PubMed  CAS  Google Scholar 

  • Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972

    Article  PubMed  CAS  Google Scholar 

  • Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS (1996) Testosterone replacement therapy improves mood in hypogonadal men — a clinical research center study. J Clin Endocrinol Metab 81:3578–3583

    Article  PubMed  CAS  Google Scholar 

  • Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS (2000) Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: J Clin Endocrinol Metab 85:964–969

    Article  PubMed  CAS  Google Scholar 

  • Wilson JD (1988) Androgen abuse by athletes. Endocr Rev 9:181–199

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization (1992) Nieschlag E, Wang CH, Handelsman DJ, Swerdloff RS, Wu FCW, Einer-Jensen N, Khanna J, Waites GMH (eds) Guidelines for the use of androgens. WHO, Geneva

    Google Scholar 

  • Yu YM, Punyasavatsu N, Elder D, D’Ercole AJ (1999) Sexual development in a two-year-old boy induced by topical exposure to testostereone. Pediatrics 104:23

    Article  Google Scholar 

  • Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ (1998) A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 19:761–768

    PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Nieschlag, E., Behre, H.M. (2001). Testosterone Therapy. In: Nieschlag, E., Behre, H.M. (eds) Andrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04491-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-04491-9_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-04493-3

  • Online ISBN: 978-3-662-04491-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics